Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Achillion Pharmaceuticals, Inc.

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of 
$100,000 Investing in Achillion Pharmaceuticals, Inc. to
Contact the Firm 
NEW YORK, NY -- (Marketwired) -- 11/15/13 --  Faruqi & Faruqi, LLP, a
leading national securities law firm, reminds investors in Achillion
Pharmaceuticals, Inc. ("Achillion" or the "Company") (NASDAQ: ACHN)
of the December 9, 2013 deadline to seek the role of lead plaintiff
in a federal securities class action lawsuit filed against Achillion
and certain executives. 
A complaint has been filed on behalf of all persons who purchased
Achillion securities between April 21, 2012 and September 27, 2013
(the "Class Period") in the District of Connecticut. 
The complaint alleges that the Company and its executives violated
federal securities laws with respect to its disclosures concerning
its business, operations, and prospects. 
Specifically, the action alleges that throughout the Class Period
Achillion issued false and/or misleading statements regarding the
effect of sovaprevir, the Company's investigative hepatitis drug, on
liver enzyme elevations. 
On July 1, 2013, the Company disclosed that the FDA had placed a
clinical hold on sovaprevir after elevations in liver enzymes were
noted in a Phase I trial. Then, on September 27, 2013, Achillion
announced that it had received a response from the FDA effectively
informing the Company that the removal of the clinical hold was not
Following this news, the Company's stock declined $4.22 per share, or
over 58%, to close at $3.02 per share on September 30, 2013. 
Request more information now by clicking here:
www.faruqilaw.com/ACHN. There is no cost or obligation to you. 
Take Action 
If you invested in Achillion stock or options between April 21, 2012
and September 27, 2013 and would like to discuss your legal rights,
visit www.faruqilaw.com/ACHN. You can also contact us by calling
Richard Gonnello or Francis McConville toll free at 877-247-4292 or
at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or
fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages
anyone with information regarding Achillion's conduct to contact the
firm, including whistleblowers, former employees, shareholders and
Faruqi & Faruqi, LLP is a national law firm which represents
investors and individuals in class action litigation. The firm is
focused on providing exemplary legal services in complex litigation
in the areas of securities, shareholder, antitrust and consumer
litigation, throughout all phases of litigation. The firm has an
experienced trial team which has achieved significant victories on
behalf of the firm's clients. To keep track of the latest securities
litigation news, follow us on Twitter at
www.twitter.com/MergerActivity or on Facebook at
Attorney Advertising. The law firm responsible for this advertisement
is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not
guarantee or predict a similar outcome with respect to any future
matter. We welcome the opportunity to discuss your particular case.
All communications will be treated in a confidential manner. 
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Francis McConville, Esq.
Telephone: (877) 247-4292 or (212) 983-9330 
Press spacebar to pause and continue. Press esc to stop.